Pantoprazole Genilac

Pantoprazole, the active ingredient in Pantoprazole Genilac, is a proton pump inhibitor presented as a strength/form for oral use. It treats acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults and adolescents. GNH USA supplies Pantoprazole Genilac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazole Genilac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Pantoprazole Genilac is a proton‑pump inhibitor that reduces gastric acid secretion in several acid‑related conditions.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease (PUD): supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome (ZES): controls excessive gastric acid production associated with gastrin‑secreting tumours. - NSAID‑induced ulcer prophylaxis: lowers the risk of ulcer formation in patients taking chronic non‑steroidal anti‑inflammatory drugs. - Erosive gastritis: aids  the  healing  of  inflamed  gastric  mucosa.

Pantoprazole is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Headache  . - Diarrhea  . - Nausea  . - Abdominal pain  . - Flatulence  . - Constipation  .

Serious or Rare Side Effects: - Acute interstitial nephritis  . - Severe allergic reactions (anaphylaxis, angio‑edema). - Clostridioides  difficile‑associated  colitis  . - Low magnesium (hypomagnesemia) with prolonged use. - Fracture risk increased  . - Liver enzyme elevation  .

When  the  patient  receives  Pant  ​